Navigation Links
EUCODIS Bioscience Launches Lipase Portfolio
Date:9/21/2009

VIENNA, Austria, September 21 /PRNewswire/ -- EUCODIS Bioscience, a company developing, customizing, manufacturing, and marketing enzymes for the chemical industry, announced today that it has launched the first enzymes of its lipase portfolio. EUCODIS Bioscience currently offers 12 lipases that have been selected to cover a broad range of potential industrial applications.

Lipases are an enzyme family that is widely used across the chemical industry, including the pharmaceutical, cosmetics, textiles, and food and feed industries. EUCODIS Bioscience offers customers to supply lipases of interest up to the kilogram scale. The Company can also customize promising lipases to properties specified by the customer, using its proven in-vivo recombination technology.

"With the launch of our lipases portfolio we enter a market of USD 300 million," said Rudy Pandjaitan, PhD, CEO of EUCODIS Bioscience. "In recent years our organization has accumulated a unique expertise in the development, customization, and manufacturing of industrial lipases. Our customers can select from our portfolio of currently 12 lipases which include both enzymes designed for well-established uses as well as those with exciting novel properties. Going forward we plan to expand our lipase platform and to leverage the industrial expertise we can offer in this area."

About EUCODIS Bioscience

EUCODIS Bioscience GmbH develops, customizes, manufactures, and markets industrial enzymes.

EUCODIS Bioscience' products help customers in the chemical, pharmaceutical, and food and feed industries to make manufacturing processes more efficient and cleaner, and to generate products with superior properties.

EUCODIS Bioscience originally focused on developing enzymes for industrial partners, including GlaxoSmithKline, Henkel, and Lohmann Animal Health. Since 2009, the Company also markets its own products.

Led by an experienced management team, EUCODIS Bioscience is backed by Austrian and German institutional venture capital funds, founders, and private investors. The Company is headquartered in Austria, Europe, with subsidiaries in France and Germany.

    For more information, please visithttp://www.eucodisbioscience.com

    Company contact EUCODIS Bioscience:
    Rudy Pandjaitan, PhD
    CEO
    EUCODIS Bioscience
    Campus Vienna Biocenter II
    Viehmarktgasse 2 a/ 2 OG
    A-1030 Vienna
    AUSTRIA
    +43-1-8900804
    office@eucodisbioscience.com

    Media contact EUCODIS Bioscience:
    Frank Butschbacher
    Investor Relations & Communications
   http://www.butschbacher.net
    +43-650-7844940
    office@butschbacher.net



'/>"/>
SOURCE EUCODIS Bioscience
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. EUCODIS Bioscience Launches Beta-Lactamase for Antibiotics and Diagnostics Industries
2. EUCODIS Bioscience Signs Research Agreement With Genencor
3. EUCODIS Bioscience and Lohmann Animal Health Announce Achievement of Major Development Milestone
4. EUCODIS Bioscience Appoints Thomas Fischer as Chief Financial Officer
5. Regado Biosciences Announces Allowance in Europe of a Fundamental Patent Broadly Covering Oligonucleotide Modulators to Blood Coagulation Factor Aptamers
6. YM BIOSCIENCES REPORTS NIMOTUZUMAB APPROVED FOR MARKETING IN MEXICO
7. American Capital Receives $182 Million In Proceeds From Sale of Axygen Bioscience
8. Sangamo BioSciences Announces Presentation at the UBS Global Life Sciences Conference
9. Neurocrine Biosciences to Present at the UBS Global Life Sciences Conference
10. Neurocrine Biosciences Secures Committed Equity Financing Facility
11. Regado Biosciences to Present at the BioPharm America 2009 Conference on September 17, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)...  The Prostate Cancer Foundation (PCF) is pleased to announce 24 ... for prostate cancer. Members of the Class of 2016 were selected from a ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... 2016   EpiBiome , a precision microbiome engineering ... debt financing from Silicon Valley Bank (SVB). The financing ... advance its drug development efforts, as well as purchase ... "SVB has been an incredible strategic partner to us ... bank would provide," said Dr. Aeron Tynes Hammack ...
(Date:6/23/2016)... ... , ... STACS DNA Inc., the sample tracking software company, today announced that ... joined STACS DNA as a Field Application Specialist. , “I am thrilled that ... of STACS DNA. “In further expanding our capacity as a scientific integrator, Hays brings ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
Breaking Biology Technology:
(Date:6/20/2016)... Securus Technologies, a leading provider of ... safety, investigation, corrections and monitoring announced that after ... secured the final acceptance by all three (3) ... Systems (MAS) installed. Furthermore, Securus will have contracts ... by October, 2016. MAS distinguishes between legitimate wireless ...
(Date:6/9/2016)... attendance control systems is proud to announce the introduction of fingerprint attendance control software, ... employees are actually signing in, and to even control the opening of doors. ... ... ... Photo - http://photos.prnewswire.com/prnh/20160609/377487 ...
(Date:6/3/2016)... 3, 2016 Das ... Nepal hat ein 44 ... geprägter Kennzeichen, einschließlich Personalisierung, Registrierung und IT-Infrastruktur, ... Produktion und Implementierung von Identitätsmanagementlösungen. Zahlreiche renommierte ... Januar teilgenommen, aber Decatur wurde als konformste ...
Breaking Biology News(10 mins):